Control ONM OHG OTD
TLR4 antibody
pretreatment
without with without with without with without with
TLR4 mRNA/18s 1.03 ± 0.14 1.07 ± 0.13 1.43 ± 0.19a 1.26 ± 0.14a* 2.20 ± 0.25ab 2.62 ± 0.20ab* 2.15 ± 0.23abc 1.44 ± 0.19abc*
TLR4 Protein /β-actin 0.16 ± 0.05 0.15 ± 0.03 0.28 ± 0.06a 0.17 ± 0.05a* 0.40 ± 0.12ab 0.38 ± 0.12ab* 0.85 ± 0.08abc 0.19 ± 0.05abc*
NF-κB p65 protein/β-actin 0.16 ± 0.02 0.13 ± 0.03 0.26 ± 0.06a 0.14 ± 0.03a* 0.44 ± 0.05ab 0.19 ± 0.04ab* 0.86 ± 0.07abc 0.21 ± 0.08abc*
TNF-α(pg/ml) 225.79 ± 24.29 226.82 ± 26.72 253.30 ± 31.57a 224.43 ± 26.71a* 336.34 ± 26.55ab 316.97 ± 35.75ab* 456.79 ± 19.68abc 412.87 ± 30.24abc*
IL-1β(pg/ml) 135.96 ± 12.73 133.19 ± 16.15 253.30 ± 31.57a 132.78 ± 23.67a* 197.94 ± 16.13 183.51 ± 19.30ab* 268.74 ± 14.50abc 243.05 ± 19.72abc*
ONM: obesity with normal metabolism; OHG: obesity with hyperglycemia; OTD: obesity with three kinds of metabolic disorders. ap<0.05 as compared with controls under the same pretreatment ; bp<0.05 as compared with ONM under the same pretreatment; cp<0.05 as compared with OHG under the same pretreatment; *p<0.05 as compared with the same group after 48h treatment.
Table 2: TLR4, NF-κB phosphorylation levels, TNF-α and IL-1β levels induced by the serum from obese in THP-1 cells preincubated with or without TLR4 monoclonal antibody.